Annals of Oncology

Divergent illicit drug policies in Europe; Partial consensus about breast and cancer treatment in Florence; Cancer targets unmet, while life expectancy falls in Europe; What about euthanasia and palliative care in Europe?; Awards, appointments; WHO in search of cancer strategies for the new millennium; Perhaps not everyone knows that...
pp. 1257-1261(5)

D. B. Kopans (ed)., Breast imaging.
pp. 1262-1262(1)
Author: Alerci M.

Prostate specific antigen (PSA) testing as screening for prostate cancer: The current controversy
pp. 1263-1264(2)
Author: Boyle P.

Gemcitabine – a major advance?
pp. 1265-1267(3)
Authors: Thomas A.; Steward W.P.

B. B. Mittal, J. A. Purdy, K. K. Ang (eds)., Advances in radiation therapy.
pp. 1268-1268(1)
Author: Bernier J.

The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: Use, limitations and future of RNA-based methods
pp. 1269-1276(8)
Authors: Lambrechts A.C.; van 't Veer L.J.; Rodenhuis S.

PSA screening for prostate cancer: The current controversy – a viewpoint
pp. 1277-1282(6)
Author: Barry M.J.

PSA screening – current controversy
pp. 1283-1288(6)
Authors: Svetec D.; Thompson I.M.

Screening for prostate cancer
pp. 1289-1292(4)
Authors: Neal D.E.; Donovan J.L.

PSA screening for prostate cancer: The current controversy
pp. 1293-1296(4)
Authors: de Koning H.J.; Schröder F.H.

Overdiagnosis of prostate carcinoma by screening: An estimate based on the results of the Florence Screening Pilot Study
pp. 1297-1300(4)
Authors: Zappa M.; Ciatto S.; Bonardi R.; Mazzotta A.

Long-term results from a phase II study of single agent paclitaxel (Taxol®) in previously platinum treated patients with advanced ovarian cancer: The Nordic experience
pp. 1301-1307(7)
Authors: Tropé C.; Hogberg T.; Kaern J.; Bertelsen K.; Bjorkholm E.; Boman K.; Himmelmann A.; Horvath G.; Jacobsen A.; Kuoppola T.; Vartianen J.; Lund B.; Onsrud M.; Puistola U.; Salmi T.; Scheistroen M.; Sandvei R.; Simonsen E.; Sorbe B.; Tholander B.; Westberg R.

5-Methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: A randomized phase I–II study of two different FU administration schedules
pp. 1309-1314(6)
Authors: Hejna M.; Kornek G.V.; Raderer M.; Valencak J.; Weinländer G.; Fiebiger W.; Miholic J.; Scheithauer W.

Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days
pp. 1315-1322(8)
Authors: Sessa C.; Minoia C.; Ronchi A.; Zucchetti M.; Bauer J.; Borner M.; de Jong J.; Pagani O.; Renard J.; Weil C.; D'Incalci M.

Clinical and pharmacologic phase I study of Cemadotin–HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer
pp. 1323-1330(8)
Authors: Mross K.; Berdel W.E.; Fiebig H.H.; Velagapudi R.; von Broen I.M.; Unger C.

Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients
pp. 1331-1337(7)
Authors: Weijl N.I.; Hopman G.D.; Wipkink-Bakker A.; Lentjes E.G.W.M.; Berger H.M.; Cleton F.J.; Osanto S.

Chylopericardium of neoplastic aetiology
pp. 1339-1342(4)
Authors: Andrade Santiago J.; Robles L.; Casimiro C.; Casado V.; Ageitos A.; Domine M.; Estevez L.; Vicente J.; Lobo F.

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer
pp. 1343-1345(3)
Authors: Friedlander M.; Millward M.J.; Bell D.; Bugat R.; Harnett P.; Moreno J.A.; Campbell L.; Varette C.; Ripoche V.; Kayitalire L.

Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck
pp. 1347-1349(3)
Authors: Hitt R.; Castellano D.; Hidalgo M.; García-Carbonero R.; Peña M.; Brandariz A.; Millán J.M.; Alvarez Vincent J.J.; Cortés-Funes H.

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients
pp. 1351-1353(3)
Authors: Zinzani P.L.; Magagnoli M.; Bendandi M.; Fraternali Orcioni G.; Gherlinzoni F.; Albertini P.; Pileri S.A.; Tura S.

Aggressive bowel lymphoma in a patient with intestinal lymphangiectasia and widespread viral warts
pp. 1355-1356(2)
Authors: Gumà J.; Rubió J.; Masip C.; Alvaro T.; Borràs J.L.

Hemolytic-uremic syndrome caused by gemcitabine
pp. 1355-1355(1)
Authors: Nackaerts K.; Daenen M.; Vansteenkiste J.; Vandevelde A.; Van Bleyenbergh P.; Demedts M.

Subject Index
pp. 1357-1374(18)

Author Index
pp. 1375-1383(9)